Indian price regulator on back foot but it ain't over yet?
This article was originally published in Scrip
Executive Summary
India's apex pricing authority has retracted internal guidelines concerning the capping of drug prices under a controversial 'public interest' provision – a move that has been cheered by industry but also perhaps highlights the simmering tensions within various arms of the government.